|
1
|
Sledge GW, Mamounas EP, Hortobagyi GN,
Burstein HJ, Goodwin PJ and Wolff AC: Past, present and future
challenges in breast cancer treatment. J Clin Oncol. 32:1979–1986.
2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Razak NA, Abu N, Ho WY, Zamberi NR, Tan
SW, Alitheen NB, Long K and Yeap SK: Cytotoxicity of eupatorin in
MCF-7 and MDA-MB-231 human breast cancer cells via cell cycle
arrest, anti-angiogenesis and induction of apoptosis. Sci Rep.
9(1514)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang X, Zhang H and Chen X: Drug
resistance and combating drug resistance in cancer. Cancer Drug
Resist. 2:141–160. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tong XY, Quan Y and Zhang HY: NUDT5 as a
novel drug target and prognostic biomarker for ER-positive breast
cancer. Drug Discov Today. 26:620–625. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tong XY, Liao X, Gao M, Lv BM, Chen XH,
Chu XY, Zhang QY and Zhang HY: Identification of NUDT5 inhibitors
from approved drugs. Front Mol Biosci. 7(44)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kinney JL: Nomifensine maleate: A new
second-generation antidepressant. Clin Pharm. 4:625–636.
1985.PubMed/NCBI
|
|
7
|
Robinson S, Cheney D and Costa EJN-Ssaop:
Effect of nomifensine and other antidepressant drugs on
acetylcholine turnover in various regions of rat brain. Naunyn
Schmiedebergs Arch Pharmacol. 304:263–269. 1978.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Katz NS, Guiard BP, El Mansari M and Blier
P: Effects of acute and sustained administration of the
catecholamine reuptake inhibitor nomifensine on the firing activity
of monoaminergic neurons. J Psychopharmacol. 24:1223–1235.
2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
CSM Update: Withdrawal of nomifensine. Br
Med J (Clin Res Ed). 293(41)1986.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Böning J and Fuchs G: Nomifensine and
psychological dependence-a case report. Pharmacopsychiatry.
19:386–388. 1986.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Badaboina S, Bai HW, Na YH, Park CH, Kim
TH, Lee TH and Chung BY: Novel radiolytic rotenone derivative,
rotenoisin B with potent anti-carcinogenic activity in hepatic
cancer cells. Int J Mol Sci. 16:16806–16815. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lee EH, Park CH, Choi HJ, Kawala RA, Bai
HW and Chung BY: Dexamethasone modified by gamma-irradiation as a
novel anticancer drug in human non-small cell lung cancer. PLoS
One. 13(e0194341)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bak DH, Kang SH, Park CH, Chung BY and Bai
HW: A novel radiolytic rotenone derivative, rotenoisin A, displays
potent anticarcinogenic activity in breast cancer cells. J
Radiation Res. 62:249–258. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kawala RA, Ramadhani FJ, Choi HJ, Lee EH,
Park CH, Chung BY and Bai HW: Kenalog modified by ionizing
radiation induces intrinsic apoptosis mediated by elevated levels
of reactive oxygen species in melanoma cancer. Oncol Rep.
41:1837–1850. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ježek J, Cooper KF and Strich R: Reactive
oxygen species and mitochondrial dynamics: The Yin and Yang of
mitochondrial dysfunction and cancer progression. Antioxidants
(Basel). 7(13)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney
N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, et al: Lower level
of MAPK expression is associated with anthracycline resistance and
decreased survival in patients with hormone receptor negative
breast cancer. Cancer Invest. 26:671–679. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang Y and Wang X: Targeting the
Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol.
13(165)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yu WK, Xu ZY, Yuan L, Mo S, Xu B, Cheng XD
and Qin JJ: Targeting β-catenin signaling by natural products for
cancer prevention and therapy. Front Pharmacol.
11(984)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bugter JM, Fenderico N and Maurice MM:
Mutations and mechanisms of WNT pathway tumour suppressors in
cancer. Nat Rev Cancer. 21:5–21. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tait SWG and Green DR: Mitochondrial
regulation of cell death. Cold Spring Harb Perspect Biol.
5(a008706)2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Redza-Dutordoir M and Averill-Bates DA:
Activation of apoptosis signalling pathways by reactive oxygen
species. Biochim Biophys Acta. 1863:2977–2992. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zorov DB, Juhaszova M and Sollott SJ:
Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS
release. Physiol Rev. 94:909–950. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Webster KA: Mitochondrial membrane
permeabilization and cell death during myocardial infarction: Roles
of calcium and reactive oxygen species. Future Cardiol. 8:863–884.
2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yue J and López JM: Understanding MAPK
signaling pathways in apoptosis. Int J Mol Sci.
21(2346)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chang H and Zou Z: Targeting autophagy to
overcome drug resistance: Further developments. J Hematol Oncol.
13(159)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cargnello M and Roux PP: Activation and
function of the MAPKs and their substrates, the MAPK-activated
protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Munshi A and Ramesh R: Mitogen-activated
protein kinases and their role in radiation response. Genes Cancer.
4:401–408. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Davidson B, Konstantinovsky S, Kleinberg
L, Nguyen MT, Bassarova A, Kvalheim G, Nesland JM and Reich R: The
mitogen-activated protein kinases (MAPK) p38 and JNK are markers of
tumor progression in breast carcinoma. Gynecol Oncol. 102:453–461.
2006.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Whyte J, Bergin O, Bianchi A, McNally S
and Martin F: Key signalling nodes in mammary gland development and
cancer. Mitogen-activated protein kinase signalling in experimental
models of breast cancer progression and in mammary gland
development. Breast Cancer Res. 11(209)2009.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Kawiak A, Domachowska A, Krolicka A,
Smolarska M and Lojkowska E: 3-chloroplumbagin induces cell death
in breast cancer cells through MAPK-mediated Mcl-1 inhibition.
Front Pharmacol. 10(784)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
He Y, Liu Z, Qiao C, Xu M, Yu J and Li G:
Expression and significance of Wnt signaling components and their
target genes in breast carcinoma. Mol Med Rep. 9:137–143.
2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Guo L, Yilamu D, Sun L, Liu S and Ma F:
Association among the expression of β-catenin, cyclin D1 and
estrogen receptor-β in human breast cancer. Exp Ther Med.
10:1423–1428. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Velasco-Velázquez MA, Li Z, Casimiro M,
Loro E, Homsi N and Pestell RG: Examining the role of cyclin D1 in
breast cancer. Future Oncol. 7:753–765. 2011.PubMed/NCBI View Article : Google Scholar
|
